IL-6 mediates suppression of T and NK cells function in EMT-associated TKI-resistant EGFR mutant NSCLC<.
Sonia A PatelMonique B NilssonYan YangXiuning LeHai T TranYasir Y ElaminXiaoxing YuFahao ZhangAlissa PoteeteXiaoyang RenLi ShenJing WangSeyed Javad MoghaddamTina CasconeMichael A CurranDon L GibbonsJohn Victor HeymachPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
These data indicate that IL-6 is upregulated in EGFR mutant NSCLC tumors with acquired EGFR-TKI resistance and suppressed T and NK cell function. IL-6 blockade enhanced antitumor immunity and efficacy of anti-PD1 therapy warranting future clinical combinatorial investigations.
Keyphrases
- small cell lung cancer
- tyrosine kinase
- epidermal growth factor receptor
- advanced non small cell lung cancer
- nk cells
- brain metastases
- epithelial mesenchymal transition
- stem cells
- current status
- machine learning
- big data
- signaling pathway
- chronic myeloid leukemia
- artificial intelligence
- smoking cessation
- replacement therapy